SEC Form 3
FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 05/03/2022 | 3. Issuer Name and Ticker or Trading Symbol Edwards Lifesciences Corp [ EW ] | |||||||||||||
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 37,426 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Employee Stock Option (Right to Acquire) | (1) | 05/16/2025 | Common Stock | 14,925 | 45.2767 | D | |
Employee Stock Option (Right to Acquire) | (2) | 05/07/2026 | Common Stock | 50,700 | 59.2567 | D | |
Employee Stock Option (Right to Acquire) | (3) | 05/06/2027 | Common Stock | 46,200 | 72.68 | D | |
Employee Stock Option (Right to Acquire) | (4) | 05/03/2028 | Common Stock | 37,400 | 93.1 | D | |
Performance Rights | 05/04/2024 | (5) | Common Stock | 5,350 | 0.0000 | D | |
Performance Rights | 05/07/2023 | (6) | Common Stock | 6,375 | 0.0000 | D | |
Performance Rights | 05/08/2022 | (7) | Common Stock | 7,200 | 0.0000 | D |
Explanation of Responses: |
1. These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
2. These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
3. These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
4. These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
5. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. |
6. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. |
7. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. |
Remarks: |
Exhibit 24, Power of Attorney, attached. |
Linda J. Park, Attorney-in-Fact | 05/04/2022 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |